Procysbi
mercaptamine
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Procysbi. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Procysbi.
For practical information about using Procysbi, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Procysbi : EPAR - Summary for the public (PDF/69.59 KB)
First published: 03/10/2013
Last updated: 03/10/2013
EMA/479655/2013 -
-
List item
Procysbi : EPAR - Risk management plan summary (PDF/172.29 KB)
First published: 08/09/2022
Authorisation details
Product details | |
---|---|
Name |
Procysbi
|
Agency product number |
EMEA/H/C/002465
|
Active substance |
mercaptamine bitartrate
|
International non-proprietary name (INN) or common name |
mercaptamine
|
Therapeutic area (MeSH) |
Cystinosis
|
Anatomical therapeutic chemical (ATC) code |
A16AA04
|
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Chiesi Farmaceutici S.p.A
|
Revision |
16
|
Date of issue of marketing authorisation valid throughout the European Union |
05/09/2013
|
Contact address |
Via Palermo 26/A |
Product information
26/05/2023 Procysbi - EMEA/H/C/002465 - IB/0038
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Other alimentary tract and metabolism products
Therapeutic indication
Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.